Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993 Jul 15;329(3):162-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8515788 # Vaddadi KS, Soosai E, Vaddadi G: Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol. 2003 Mar;55(3):307-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12630982 # Naheed M, Green B: Focus on clozapine. Curr Med Res Opin. 2001;17(3):223-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11900316 # Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999 Jan;60(1):36-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10074876 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - 8 hours (range 4-12 hours) (en)
|
http://linked.open...ugbank/indication
| - For use in patients with treatment-resistant schizophrenia. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Clozapine's antipsychotic action is likely mediated through a combination of antogistic effects at D2 receptors in the mesolimbic pathway and 5-HT2A receptors in the frontal cortex. D2 antagonism relieves positive symptoms while 5-HT2A antagonism alleviates negative symptoms. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...y/drugbank/patent
| |
http://linked.open...outeOfElimination
| - Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. (en)
|
http://linked.open.../drugbank/synonym
| - Clozapine (en)
- Clozapin (en)
- Clozapina (en)
- Clozapinum (en)
|
http://linked.open...drugbank/toxicity
| - Clozapine carries a black-box warning for agranulocytosis. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Avoid alcohol. (en)
- Take without regard to meals. (en)
- Limit caffeine intake (may reduce clozapine matabolism). (en)
|
http://linked.open...nk/proteinBinding
| - 97% (bound to serum proteins) (en)
|
http://linked.open...ynthesisReference
| - Schmutz, J. and Hunziker, F.; US. Patent 3,539,573; November 10, 1970 . (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...logy/drugbank/pKa
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Rapid and almost complete (en)
|